Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
:KVUE
KVUE Stock Chart & Stats
$17.22
-$0.04(-0.19%)
At close: 4:00 PM EST
$17.22
-$0.04(-0.19%)
Day’s Range― - ―
52-Week Range$14.02 - $25.17
Previous CloseN/A
Volume2.33M
Average Volume (3M)47.35M
Market Cap
$32.99B
Enterprise Value$39.55B
Total Cash (Recent Filing)$1.14B
Total Debt (Recent Filing)$9.11B
Price to Earnings (P/E)23.1
Beta0.02
Next Earnings
Feb 05, 2026EPS Estimate
0.23Last Dividend Ex-Date
Nov 12, 2025Dividend Yield4.79%
Share Statistics
EPS (TTM)0.28
Shares Outstanding1,915,802,100
10 Day Avg. Volume42,169,494
30 Day Avg. Volume47,348,977
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)4.20
Price to Sales (P/S)2.62
P/FCF Ratio30.38
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit4.53
Enterprise Value/Ebitda13.44
Forecast
1Y Price Target
$19.42Price Target Upside12.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)1.03
Revenue Forecast (FY)$15.04B
Bulls Say, Bears Say
Bulls Say
AcquisitionKenvue has agreed to be acquired by Kimberly-Clark in a cash and stock transaction.
Legal DefenseNo research has definitively proven a causal link between acetaminophen use and increased risk of ASD, which could benefit Kenvue's defense in the case.
Product PortfolioKenvue's focus on a product portfolio of leading consumer healthcare brands, coupled with cost savings and demand generation investments, supports balanced growth.
Bears Say
Financial PerformanceThird-quarter results for Kenvue, Inc. were sluggish, indicating potential challenges for the company.
Legal ChallengesThe court hearing suggested that Kenvue might face a prolonged legal battle, as judges questioned why the plaintiff's expert testimonies were excluded, potentially allowing the case to be sent back to District Court.
Market ConcernsShares have moved down by nearly -30% since early-September due to Tylenol headlines and UK talc litigation.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $14.02 and its highest was $25.17 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $32.99B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Feb 05, 2026 which is in 69 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Sep 28, 2025. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.02.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 4.79%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.23.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,915,802,100 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.28 in its last earnings report, beating expectations of $0.26. Following the earnings report the stock price went up 2.203%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
Kenvue, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.42 (12.78% Upside)
$19.42 (12.78% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 23.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.65%
12-Months-Change
Fundamentals
Return on Equity
13.47%
Trailing 12-Months
Asset Growth
1.20%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
KVUE Revenue Breakdown
42.23% Self Care
30.33% Essential Health
27.43% Skin Health and Beauty
KVUE Stock 12 Month Forecast
Average Price Target
$19.42
▲(12.78% Upside)
Technical Analysis
Ownership Overview
1.13% Insiders
32.38% Mutual Funds
8.91% Other Institutional Investors
29.58% Public Companies and Individual Investors